Comparison of In Vitro Activities of DU-6859a and Other Fluoroquinolones Against Japanese Isolates of Anaerobic Bacteria

• Published in: Clinical infectious diseases Vol. 23; no. Supplement-1; pp. S31 - S35
• Main Authors: Kato, Naoki, Kato, Haru, Tanaka-Bando, Kaori, Watanabe, Kunitomo, Ueno, Kazue
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.12.1996; University of Chicago Press
• Subjects: Administration, Oral; Anaerobic bacteria; Anti-Infective Agents - administration & dosage; Anti-Infective Agents - pharmacology; Antibacterial agents; Antibacterials; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimicrobials; Bacteria, Anaerobic - drug effects; Bacteria, Anaerobic - isolation & purification; Bacterial Infections - drug therapy; Bacterial vaginosis; Bacteroides; Bacteroides fragilis - drug effects; Bacteroides fragilis - isolation & purification; Bacteroides Infections - drug therapy; Biological and medical sciences; Female; Fluoroquinolones; Gardnerella vaginalis - drug effects; Gardnerella vaginalis - isolation & purification; Humans; In Vitro Techniques; Japan; Medical sciences; Microbial Sensitivity Tests; Mobiluncus; Peptostreptococcus; Pharmaceutical preparations; Pharmacology. Drug treatments; Quinolones; Quinolones - administration & dosage; Quinolones - pharmacology; Vaginosis, Bacterial - drug therapy; Asia; Japan; Gardnerella vaginalis; Fluoroquinolone derivatives; Anaerobe; Bacteria; In vitro; Biological activity; Comparative study
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/clinids/23.Supplement_1.S31

The in vitro activity of DU-6859a, a new fluoroquinolone, was compared with those of other ftuoroquinolones against clinical isolates of anaerobic bacteria and Gardnerella vaginalis. DU-6859a was the most active agent; it inhibited 90% of isolates of almost all species tested, including Bacteroides fragilis at ≤0.39 µg/mL. Although the other quinolones tested were active against most gram-positive anaerobes, inhibiting their growth at ≤1.56 µg/mL, these agents were less active against the B. fragilis group and Prevotella bivia (90% of which were inhibited at ≥6.25 µg/mL). Mobiluncus species and G. vaginalis, which are well associated with bacterial vaginosis, were inhibited by DU-6859a at 0.1 µg/mL. These results suggest that DU-6859a is a promising oral agent for the treatment of bacterial infections due to anaerobic bacteria; however, further studies, including determination of vaginal levels of this compound, should be performed to study the role of DU-6859a in the treatment of bacterial vaginosis.